JP2009535330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535330A5 JP2009535330A5 JP2009507637A JP2009507637A JP2009535330A5 JP 2009535330 A5 JP2009535330 A5 JP 2009535330A5 JP 2009507637 A JP2009507637 A JP 2009507637A JP 2009507637 A JP2009507637 A JP 2009507637A JP 2009535330 A5 JP2009535330 A5 JP 2009535330A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- dysfunction
- antisecretory
- fragments
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 230000001262 anti-secretory effect Effects 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000004064 dysfunction Effects 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000007910 systemic administration Methods 0.000 claims 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000007488 abnormal function Effects 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000004706 cardiovascular dysfunction Effects 0.000 claims 2
- 210000004323 caveolae Anatomy 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000005980 lung dysfunction Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000009772 tissue formation Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
- 230000004218 vascular function Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0600933-6 | 2006-04-27 | ||
| SE0600933 | 2006-04-27 | ||
| US92082607P | 2007-03-30 | 2007-03-30 | |
| US60/920,826 | 2007-03-30 | ||
| PCT/SE2007/000415 WO2007126365A2 (en) | 2006-04-27 | 2007-04-27 | Further medical uses of antisecretory protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014013388A Division JP6063401B2 (ja) | 2006-04-27 | 2014-01-28 | 脂質ラフトの調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009535330A JP2009535330A (ja) | 2009-10-01 |
| JP2009535330A5 true JP2009535330A5 (OSRAM) | 2010-06-17 |
| JP5508846B2 JP5508846B2 (ja) | 2014-06-04 |
Family
ID=38655930
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507637A Expired - Fee Related JP5508846B2 (ja) | 2006-04-27 | 2007-04-27 | 脂質ラフトの調節 |
| JP2014013388A Expired - Fee Related JP6063401B2 (ja) | 2006-04-27 | 2014-01-28 | 脂質ラフトの調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014013388A Expired - Fee Related JP6063401B2 (ja) | 2006-04-27 | 2014-01-28 | 脂質ラフトの調節 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8487074B2 (OSRAM) |
| EP (1) | EP2037950B1 (OSRAM) |
| JP (2) | JP5508846B2 (OSRAM) |
| KR (1) | KR20090037992A (OSRAM) |
| AU (1) | AU2007244005B2 (OSRAM) |
| CA (1) | CA2650132C (OSRAM) |
| IL (1) | IL194775A (OSRAM) |
| MX (1) | MX2008013777A (OSRAM) |
| PL (1) | PL2037950T3 (OSRAM) |
| WO (1) | WO2007126365A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650132C (en) | 2006-04-27 | 2017-10-24 | Hans-Arne Hansson | Modulation of lipid rafts |
| KR101805973B1 (ko) | 2006-04-27 | 2017-12-06 | 란트만넨 아스-팍토르 아베 | 항분비 단백질의 추가적 의학 용도 |
| CA2650344C (en) | 2006-04-27 | 2017-10-31 | Lantmannen As-Faktor Ab | Use of antisecretory protein to treat intraocular hypertension |
| US9220750B2 (en) | 2007-04-27 | 2015-12-29 | Lantmannen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| WO2010065342A1 (en) | 2008-11-25 | 2010-06-10 | Temple University | Angiocidin inhibition of tumor cell growth |
| CA2992057C (en) | 2015-07-10 | 2021-07-20 | Lantmannen As-Faktor Ab | Process for producing egg yolk with high content of af-16 |
| KR102268955B1 (ko) | 2016-07-18 | 2021-06-25 | 란트만넨 아스-팍토르 아베 | 항분비 인자 17 |
| WO2020002464A1 (en) | 2018-06-28 | 2020-01-02 | Lantmännen Medical Ab | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| SE508609C2 (sv) | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| JP2000506375A (ja) * | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
| SE506486C2 (sv) | 1996-11-20 | 1997-12-22 | Svenska Lantmaennen Riksfoerbu | Födoämne som vid förtäring inducerar antisekretoriska proteiner |
| SE513496C2 (sv) | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| CA2650132C (en) | 2006-04-27 | 2017-10-24 | Hans-Arne Hansson | Modulation of lipid rafts |
| KR101805973B1 (ko) * | 2006-04-27 | 2017-12-06 | 란트만넨 아스-팍토르 아베 | 항분비 단백질의 추가적 의학 용도 |
| EP2682819A2 (en) * | 2012-07-04 | 2014-01-08 | Xeikon IP B.V. | A method for forming a multi-colour image |
-
2007
- 2007-04-27 CA CA2650132A patent/CA2650132C/en not_active Expired - Fee Related
- 2007-04-27 EP EP07748080.4A patent/EP2037950B1/en not_active Not-in-force
- 2007-04-27 KR KR1020087029121A patent/KR20090037992A/ko not_active Ceased
- 2007-04-27 WO PCT/SE2007/000415 patent/WO2007126365A2/en not_active Ceased
- 2007-04-27 AU AU2007244005A patent/AU2007244005B2/en not_active Ceased
- 2007-04-27 JP JP2009507637A patent/JP5508846B2/ja not_active Expired - Fee Related
- 2007-04-27 PL PL07748080T patent/PL2037950T3/pl unknown
- 2007-04-27 MX MX2008013777A patent/MX2008013777A/es active IP Right Grant
-
2008
- 2008-10-22 IL IL194775A patent/IL194775A/en active IP Right Grant
- 2008-10-27 US US12/289,390 patent/US8487074B2/en not_active Expired - Fee Related
-
2014
- 2014-01-28 JP JP2014013388A patent/JP6063401B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535330A5 (OSRAM) | ||
| JP7759693B2 (ja) | モンテルカストおよびペプチドの新規接合体 | |
| CN105143170B (zh) | 用于治疗肺纤维化、肝纤维化、皮肤纤维化和心脏纤维化的经取代的芳族化合物 | |
| KR101965467B1 (ko) | 아드레노메둘린의 폴리에틸렌 글리콜 기반 전구약물 및 그의 용도 | |
| JP5881122B2 (ja) | 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用 | |
| AU2014231648B2 (en) | Substituted aromatic compounds and related method for the treatment of fibrosis | |
| CN113350352B (zh) | 呼吸性疾病的治疗 | |
| JP7571035B2 (ja) | Ｃｎｐコンジュゲートの乾燥医薬製剤 | |
| CN103476933B (zh) | 白介素1受体的拮抗剂 | |
| JP6557684B2 (ja) | 線維性疾患の治療に用いられるｐｐａｒ化合物 | |
| TW200827370A (en) | Novel compounds and their effects on feeding behaviour | |
| JP5307542B2 (ja) | 治療的に活性なα−ＭＳＨアナログ | |
| NZ552558A (en) | Compositions for delivering peptide YY and PYY agonists | |
| RU2008146731A (ru) | Модуляция липидных рафтов | |
| KR20030038547A (ko) | 울혈심부전을 치료하기 위한 프로스타글란딘 화합물 | |
| EP2832357A1 (en) | Selective AT2 receptor agonists for use in treatment of cachexia | |
| KR20220079860A (ko) | 신규 펩티드 | |
| JP6774138B2 (ja) | オストレオリシン、機能的に関連したその変異体、オストレオリシンを含む抽出物、及びそれらの使用 | |
| ES2311973T3 (es) | Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica. | |
| JP2005501060A (ja) | 硫黄含有有機硝酸化合物の使用法 | |
| KR20090083891A (ko) | Ｓ-니트로소티올 화합물 및 관련 유도체 | |
| CN110511285B (zh) | 一种重组融合多肽及其应用 | |
| US12398196B2 (en) | Fused polypeptide with multifunctional activities and use thereof | |
| JP2001518062A (ja) | 肺繊維症の治療 | |
| US20070117861A1 (en) | Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors |